# Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

> **NCT00006368** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Breast Cancer
- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Lung Cancer
- Lymphoma
- Melanoma (Skin)
- Neoplastic Syndrome

## Interventions

- **RADIATION:** yttrium Y 90-edotreotide

## Key facts

- **NCT ID:** NCT00006368
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006368, "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*